Showing 781-790 of 5802 results for "".
Continuity of Psoriasis Care in the Era of COVID-19
https://practicaldermatology.com/columns/clinical-focus-1/continuity-of-psoriasis-care-in-the-era-of-covid-19/23285/While there’s no data about susceptibility to COVID-19 in psoriasis, there is relevant information on infectious complications from biologics.COVID-19 Impact: Navigating Clinical Research
https://practicaldermatology.com/series/dermatology-dispatches/covid-19-impact-navigating-clinical-research/19771/Conducting clinical research studies is challenging as the majority of Americans are under stay-at-home orders for the forseeable future due to the COVID-19 pandemic, says Todd E. Schlesinger, MD. He suggests trialists do their best to say in contact with clinical research organizations, sponsors, aDermatology chatbots 101
https://practicaldermatology.com/topics/practice-management/dermatology-chatbots-101/19743/Could an artificial intelligence powered chatbot improve your dermatology website? Find out in this Ekwa Marketing video.Blinded by the Light—and More
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/blinded-by-the-lightand-more/23154/CSF faculty members share their favorite Energy- and Light-Based Devices.Biologics for Psoriasis: A Status Update
https://practicaldermatology.com/topics/psoriasis/biologics-for-psoriasis-a-status-update/23006/The field has grown substantially from the early 2000s to include now a dozen innovator systemic agents, a host of biosimilars, and soon JAK Inhibitors.Hot Topic: Medical Photography, EHRs, and Augmented Reality Technology
https://practicaldermatology.com/topics/practice-management/hot-topic-medical-photography-ehrs-and-augmented-reality-technology-/19568/Todd E. Schlesinger, MD and Joel L. Cohen discuss advances in the pipeline in terms of photo storage, search functionality in electronic medical records, and the emergence of augmented reality technology in patient and physician education.Treating Moderate to Severe Psoriasis: Weighing the Treatment Options
https://practicaldermatology.com/topics/psoriasis/-treating-moderate-to-severe-psoriasis-weighing-the-treatment-options/18375/In part 2 of her interview with DermTube Journal Club host Joshua Zeichner, MD, Erin Boh, MD reviews new biologics that provide patients with moderate to severe psoriasis improved treatment options. She discusses their efficacy and safety and offers tips for finding the right one for each patient baCosmetic Controversies
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/cosmetic-controversies--fwjagege/18202/With the variety of devices on the market, aesthetic physicians may not even realize all the options available. They can reduce chin fat and cellulite, treat melasma, and even help patients build muscle. Jeanine Downie, MD discusses options.Meeting Recap: Aesthetic Extenders Symposium 2018
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/meeting-recap-aesthetic-extenders-symposium-2018/18234/Faculty and industry partners discuss the highlights of the Aesthetic Extenders Symposium. From novel uses of toxins to skincare and injections techniques, AES provided a range of updates. AES 2019 will be held in Miami, FL.Altreno's Approval, Psoriasis Insights
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-altreno-s-approval-psoriasis-insights--nxhineya/18236/Ortho Dermatologics' Altreno lotion is now approved for the topical treatment of acne vulgaris in patients ages 9 and up. Altreno, containing tretinoin 0.05%, will be available during the fourth quarter of this year. The FDA has accepted Ortho Dermatologics' resubmitted New Drug Application for Duob